Antihypertensive Medications and Mood Disorders

Antihypertensive agents, prescribed primarily to regulate elevated blood pressure, have attracted growing attention for their neuropsychiatric effects. Beyond cardiovascular modulation, several classes—most notably β-adrenoceptor antagonists, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)—interact with central nervous system pathways implicated in mood regulation. Clinical observations and preclinical models suggest that interference with the renin-angiotensin system can attenuate neuroinflammatory processes, while blockade of peripheral catecholamine signalling may influence anxiety and depressive symptoms. However, individual responses vary markedly according to drug lipophilicity, blood–brain barrier permeability and patient vulnerability. Recent investigations strive to delineate the dual potential of these medications to exacerbate or ameliorate affective disturbances, with implications for personalised prescribing in populations at risk of mood disorders. A synthesis of emerging findings will inform both cardiology and psychiatry, underscoring the need for interdisciplinary strategies when treating hypertensive patients with concomitant affective symptoms.

Research from Nature Portfolio

Recent studies have demonstrated that ARBs, by antagonising central angiotensin II receptors, can reduce markers of neuroinflammation and improve depressive-like behaviours in rodent models. Findings indicate downregulation of pro-inflammatory cytokines in the hippocampus and normalisation of hippocampal neurogenesis, suggesting a mechanistic link between blood pressure control and mood enhancement. A complementary review has synthesised data on lipophilic β-blockers, highlighting their capacity to cross the blood–brain barrier, alter noradrenergic tone and modulate amyloid precursor processing. This has prompted new insights into how subtle alterations in neurotransmitter dynamics may translate into clinically relevant effects on anxiety and depressive symptomatology, and has guided hypotheses for future translational studies.

Antihypertensive Medications and Mood Disorders publication trend

The graph below shows the total number of articles in antihypertensive medications and mood disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Angiotensin-converting enzyme (ACE) inhibitor: A drug that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and neuroinflammatory signalling.

Angiotensin II receptor blocker (ARB): A compound preventing angiotensin II from binding its receptors, with downstream effects on blood pressure and central inflammatory pathways.

β-adrenoceptor antagonist (β-blocker): A medication that inhibits β-adrenergic receptors, thereby modulating heart rate, catecholamine activity and potential central nervous system effects.

Blood–brain barrier (BBB): A selective endothelial barrier that regulates passage of substances from the bloodstream into the brain, influencing drug central nervous system penetration.

Neuroinflammation: Activation of immune and glial cells within the central nervous system, often implicated in the pathogenesis of depression and other mood disorders.

References

1. Associations between β-blockers and psychiatric and behavioural outcomes: A population-based cohort study of 1.4 million individuals in Sweden. PLOS Medicine (2023).
2. Neuropsychiatric Consequences of Lipophilic Beta-Blockers. Medicina (2021).